Aurum Biosciences

Aurum Biosciences is a Glasgow-based biotech developing the ABL-101 platform, an injectable oxygen carrier designed to treat oxygen deprivation in conditions like acute stroke. The lead asset has completed Phase 1/2a studies, with Phase 2 trials in stroke and inflammation imaging planned for 2026. As a spinout from NHS Greater Glasgow and Clyde, InnoScot Health, and the University of Glasgow, the company is targeting the vast unmet need in stroke, where only 10% of patients currently access effective therapeutics.

Patented ABL-101 platform: injectable nano-scale oxygen carriers (up to 45x smaller than red blood cells) designed to bypass vascular blockages and deliver oxygen to ischemic tissues. Serves as both a therapeutic and diagnostic agent.

Direct competition in nano-scale oxygen carriers for stroke is limited, but the broader neuroprotection and reperfusion market includes thrombolytics, thrombectomy devices, and other investigational agents. The diagnostic imaging space is crowded, requiring clear differentiation.